Partisan gridlock continues to keep Congress from taking action on clarifying the regulatory framework for CBD. Even as the Biden administration moves to reschedule cannabis down to a more permissive classification – one it could share with something as ubiquitous as Tylenol with codeine – Congress punts the issues surrounding CBD back and forth with the US Food and Drug Administration (FDA).

And this inaction is having a concrete effect. For example, cannabinoids still remain under-explored – due in large part to being relatively unaddressed within the legal landscape.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization